苯丙胺(Amphetamine) - 在研适应症：注意缺陷障碍伴多动_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(+-)-alpha-Methylphenylethylamine、1-phenyl-2-aminopropane、Adzenys XR-ODT

+ [13]

靶点-

作用机制

中枢神经系统刺激剂

治疗领域

其他疾病

在研适应症

注意缺陷障碍伴多动

非在研适应症-

原研机构

Neos Therapeutics, Inc.

在研机构

Neos Therapeutics, Inc.

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2016-01-27),

注意缺陷障碍伴多动

最高研发阶段(中国)-

特殊审评-

登录后查看首次获批时间轴

结构

分子式C9H13N

InChIKeyKWTSXDURSIMDCE-UHFFFAOYSA-N

CAS号300-62-9

关联

63

项与苯丙胺相关的临床试验

NCT05916339 / Recruiting临床4期IIT

Efficacy of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum Disorder

This study is a pragmatic clinical trial examining the comparative effectiveness of two stimulant medications (methylphenidate and amphetamine) in the treatment of ADHD in children and adolescents with autism. Using a sequential, multiple assignment randomization trial (SMART) design the study will not only assess these two medications but also the role of an increasingly popular class of ADHD medication, the alpha-2 agonists. Findings from this study will help improve clinicians' approach to medication selection and reduce the repeated trials of multiple medications that are current standard care.

开始日期2023-10-01

申办/合作机构

Nationwide Children's Hospital

[+14]

NCT04577417 / CompletedN/AIIT

Stimulant Medication Effects on Auditory Sensitivity and Acoustic Reflex in Adolescents With ADHD

The aims of this study are to evaluate auditory sensitivity in teenagers with ADHD using acoustic reflex thresholds (ART) and to examine the effects of ADHD stimulant medication on ART.

开始日期2020-09-13

申办/合作机构

Nemours Children's Clinic

NCT04094025 / Completed临床1期

A Randomized, Evaluator-blinded Study to Evaluate Skin Irritation and Sensitization of d-Amphetamine Transdermal System in Healthy Adults

The study will assess skin irritation as well as sensitization for d-ATS patch in healthy subjects.

开始日期2019-12-02

申办/合作机构

Noven Therapeutics LLC

100 项与苯丙胺相关的临床结果

登录后查看更多信息

100 项与苯丙胺相关的转化医学

登录后查看更多信息

100 项与苯丙胺相关的专利（医药）

登录后查看更多信息

18,189

项与苯丙胺相关的文献（医药）

2024-09-01·Neural Regeneration Research

Brain dysfunctions and neurotoxicity induced by psychostimulants in experimental models and humans: an overview of recent findings

Article

作者: Serra, Marcello ; Pollack, Alexia E. ; Simola, Nicola ; Costa, Giulia

Preclinical and clinical studies indicate that psychostimulants, in addition to having abuse potential, may elicit brain dysfunctions and/or neurotoxic effects. Central toxicity induced by psychostimulants may pose serious health risks since the recreational use of these substances is on the rise among young people and adults. The present review provides an overview of recent research, conducted between 2018 and 2023, focusing on brain dysfunctions and neurotoxic effects elicited in experimental models and humans by amphetamine, cocaine, methamphetamine, 3,4-methylenedioxymethamphetamine, methylphenidate, caffeine, and nicotine. Detailed elucidation of factors and mechanisms that underlie psychostimulant-induced brain dysfunction and neurotoxicity is crucial for understanding the acute and enduring noxious brain effects that may occur in individuals who use psychostimulants for recreational and/or therapeutic purposes.

2024-08-01·Current Organic Synthesis

Synthesis of Phentermine and its Derivatives

Article

作者: Khushbu ; Shruti ; Parkash Meena, Bharti ; Dwivedi, Jaya

Abstract:In recent years, a growing global concern has been obesity. Patients with obesity are at major risk for developing a number of diseases. These diseases may significantly impact patient’s daily lives and increase the mortality rate. Over a year, medication for obesity has undergone substantial changes. An amphetamine-like prescription drug called Phentermine (Adipex-P, Lomaira) is used to suppress appetite. In the last few years, Phentermine and its derivatives have attracted much attention due to their use in weight reduction; by reducing appetite or prolonging the feeling of fullness, it can aid in weight reduction. So, reviewing the synthesis of Phentermine and its derivatives becomes imperative. Therefore, various synthetic routes for Phentermine (from benzaldehyde, isopropyl phenyl ketone, dimethyl benzyl carbinol) and its derivatives synthesis, involving ortho-palladation, are also reviewed here comprehensively.

2024-07-01·Neural Regeneration Research

Effects of mesenchymal stem cell on dopaminergic neurons, motor and memory functions in animal models of Parkinson's disease: a systematic review and meta-analysis

Article

作者: Kim, Yong Wook ; Lee, Sang Chul ; Rahmati, Masoud ; Shin, Jae Il ; Park, Jong Mi

AbstractParkinson's disease is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta, and although restoring striatal dopamine levels may improve symptoms, no treatment can cure or reverse the disease itself. Stem cell therapy has a regenerative effect and is being actively studied as a candidate for the treatment of Parkinson's disease. Mesenchymal stem cells are considered a promising option due to fewer ethical concerns, a lower risk of immune rejection, and a lower risk of teratogenicity. We performed a meta-analysis to evaluate the therapeutic effects of mesenchymal stem cells and their derivatives on motor function, memory, and preservation of dopaminergic neurons in a Parkinson's disease animal model. We searched bibliographic databases (PubMed/MEDLINE, Embase, CENTRAL, Scopus, and Web of Science) to identify articles and included only peer-reviewedin vivointerventional animal studies published in any language through June 28, 2023. The study utilized the random-effect model to estimate the 95% confidence intervals (CI) of the standard mean differences (SMD) between the treatment and control groups. We use the systematic review center for laboratory animal experimentation's risk of bias tool and the collaborative approach to meta-analysis and review of animal studies checklist for study quality assessment. A total of 33 studies with data from 840 Parkinson's disease model animals were included in the meta-analysis. Treatment with mesenchymal stem cells significantly improved motor function as assessed by the amphetamine-induced rotational test. Among the stem cell types, the bone marrow MSCs with neurotrophic factor group showed largest effect size (SMD [95% CI] = –6.21 [–9.50 to –2.93],P= 0.0001,I2= 0.0 %). The stem cell treatment group had significantly more tyrosine hydroxylase positive dopaminergic neurons in the striatum ([95% CI] = 1.04 [0.59 to 1.49],P= 0.0001,I2= 65.1 %) and substantia nigra (SMD [95% CI] = 1.38 [0.89 to 1.87],P= 0.0001,I2= 75.3 %), indicating a protective effect on dopaminergic neurons. Subgroup analysis of the amphetamine-induced rotation test showed a significant reduction only in the intracranial-striatum route (SMD [95% CI] = –2.59 [–3.25 to –1.94],P= 0.0001,I2= 74.4 %). The memory test showed significant improvement only in the intravenous route (SMD [95% CI] = 4.80 [1.84 to 7.76],P= 0.027,I2= 79.6 %). Mesenchymal stem cells have been shown to positively impact motor function and memory function and protect dopaminergic neurons in preclinical models of Parkinson's disease. Further research is required to determine the optimal stem cell types, modifications, transplanted cell numbers, and delivery methods for these protocols.

130

项与苯丙胺相关的新闻（医药）

2024-05-08

·BioSpace

Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024

DENVER, CO / ACCESSWIRE / May 8, 2024 / Aytu BioPharma Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its third quarter of fiscal 2024 for the period ended March 31, 2024, after the market close on Wednesday, May 15, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, May 15, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session. Conference Call Details Date and Time: Wednesday, May 15, 2024, at 4:30 p.m. Eastern Time Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for U.S. callers or +1 (973) 528-0011 for international callers and using the participant access code 300411. Webcast Information: The webcast will be accessible live and archived at , and accessible on the Investors section of the Company's website at under Events & Presentations. Replay: A teleconference replay of the call will be available until May 29, 2024 at (877) 481-4010 for U.S. callers or +1 (919) 882-2331 for international callers and using replay access code 50379. About Aytu BioPharma, Inc. Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com. Contacts for Investors: Mark Oki, Chief Financial Officer Aytu BioPharma, Inc. moki@aytubio.com Robert Blum or Roger Weiss Lytham Partners aytu@lythampartners.com SOURCE: Aytu BioPharma, Inc. View the original press release on accesswire.com

财报

2024-04-11

·梅斯医学

世界帕金森病日：关注年轻帕金森病群体

2024年4月11日是第28个世界帕金森病日，今年的主题是：和谐共生，美好生活。帕金森病又称为震颤麻痹，是常见的神经系统退行性病变。现代流行病学调查显示，我国65岁以上人群患病率为1.7%。在中国人口老龄化背景下，PD的发病率又有着随年龄增长而上升的特点。我国大约有超过300万的帕金森病患者，预计到2030年，中国帕金森病患者将达到490万（全球约870万）。帕金森病是一种常见的发生于老年人的神经系统退行性疾病，但是该病也会影响青少年和青年人群，出现罕见的早发型帕金森病（EOPD），约占所有帕金森病的5-10%。早发型帕金森病根据发病年龄又可进一步分为：青年型帕金森病（YOPD）：发病年龄21-50岁；青少年型帕金森病（JP）：发病年龄＜21岁。病因1、遗传因素早发型帕金森病具有明确的遗传易感性和家族聚集性，多数具有阳性家族史，提示遗传因素在其中起到重要作用。目前已有20多个基因明确定位，包括常染色体显性和隐性遗传两种主要遗传方式。常见的常染色体显性遗传基因：SNCA、LRRK2、UCH-L1、VPS35等。常见的常染色体隐性遗传基因：Parkin、PINK1、DJ-1、ATP13A2、PLA2G6等。易感基因：不直接致病，在正常人群中也可检出，但是其存在增加PD的发生风险，例如GBA、MAPT、SNCA等。多个易感基因携带者发生PD的风险显著增高，提示多个微效基因的叠加效应。此外，易感基因之间还存在交互作用。2、心理因素近年来，随着升学和就业压力逐渐增加，青少年型帕金森病在生活中出现得越来越频繁。医学界普遍认为，帕金森病跨年龄发病的病因与心理压力也有关联。 3、其他EOPD还常常与病毒性脑炎、脑外伤、一氧化碳中毒以及药物滥用有关。其中，吸毒引发EOPD病例虽然不多，但也需要引起足够的重视。早在1976年就已发现，在非法合成毒品MPPP（一种类似于吗啡和哌替啶的毒品）时，可以意外生成一种杂质MPTP，后者被证实为能够破坏黑质多巴胺能神经元的神经毒素，这种神经毒素至今仍广泛用于帕金森动物模型的研究中。另外，也有数据显示苯丙胺和甲基苯丙胺（冰毒）均可增加帕金森病的发病风险。临床表现EOPD的临床表现包括运动症状和非运动症状。1、运动症状EOPD的首发症状以运动迟缓多见，也可以肌张力障碍为首发症状。EOPD以强直少动症状为主要表现，静止性震颤、早期平衡功能障碍相对少见；部分患者可伴有肌张力障碍，多见于足部或下肢的局灶型肌张力障碍，通常表现为模式化的扭曲动作，可以呈现震颤样，且可被随意动作诱发或加重。2、非运动症状包括神经精神症状、睡眠障碍、认知功能障碍、便秘等，以抑郁、不宁腿综合征、成瘾行为较多见，而认知功能障碍、神经精神症状、幻觉等相对少见，嗅觉功能相对保留较好。诊断根据发病年龄≤50岁，必备运动迟缓及至少具备静止性震颤或肌强直中的一项，参照《中国帕金森病的诊断标准(2016版)》诊断EOPD：抗帕金森病药物治疗1、左旋多巴制剂：如多巴丝肼、卡左双多巴控释片、左旋多巴/卡比多巴肠内凝胶等。EOPD患者对左旋多巴制剂的反应良好，左旋多巴制剂可显著改善运动症状，但相对容易出现运动并发症。针对伴有智能减退的EOPD患者，一般首选左旋多巴制剂进行治疗；针对力求显著改善运动症状的EOPD患者，一般选择左旋多巴制剂或左旋多巴制剂联合儿茶酚-O-甲基转移酶（COMT）抑制剂进行治疗。注意：对于25岁以下，特别是青少年期及儿童期患者，由于左旋多巴制剂会影响骨骼发育，因此不推荐使用。2、非麦角类DR激动剂：如吡贝地尔、普拉克索、罗匹尼罗、罗替高汀等，可作为不伴智能减退的EOPD患者的单药治疗药物。适用于病程初期的EOPD患者，但较易出现与非麦角类DR激动剂相关的发作性睡眠及冲动控制障碍。注意：对于青少年期患者应慎用，儿童期患者不推荐使用。3、MAO-B抑制剂：如司来吉兰和雷沙吉兰，亦可作为不伴智能减退的 EOPD 患者的单药治疗药物；也可作为左旋多巴制剂的联合药物，特别是对于症状波动的EOPD患者。注意：对于青少年期患者及儿童期患者不推荐使用。4、COMT抑制剂：如恩他卡朋、恩他卡朋双多巴等。恩他卡朋可与多巴丝肼等左旋多巴制剂联合用药，可提高左旋多巴的生物利用度，延长左旋多巴的临床疗效，改善EOPD患者的运动症状。注意：对于青少年期患者及儿童期患者不推荐使用。5、抗胆碱能药物：如苯海索，对EOPD患者的静止性震颤有效，无静止性震颤的EOPD患者不予推荐。注意：长期服用可导致认知功能损害。对于青少年期及儿童期患者应慎用。6、金刚烷胺：对运动迟缓、肌强直有一定作用，对改善异动症有一定帮助。注意：对于青少年期患者应慎用，儿童期患者不推荐使用。参考文献：[1]中华医学会神经病学分会帕金森病及运动障碍学组，中国医师协会神经内科医师分会帕金森病及运动障碍学组. 早发型帕金森病的诊断与治疗中国专家共识（2021）[J]. 中华神经医学杂志，2021,20 (2)：109-116.[2]中国帕金森病的诊断标准(2016版)撰文 | Anna.An编辑 | Swagpp● 延寿7-8年，还能抗癌！两次登上顶刊：饮料中这种常见成分，还能增强癌症治疗的疗效！● 每周“洗脑”30分钟，让大脑返老还童？Nature最新：改善老年的认知能力，还能缓解阿尔茨海默症的病理！但要注意...● 热议！“交了护理费凭啥还要再花380元请护工？”患者要求取消护工：太贵且不负责，适当提高护理费，护士为啥就不能照顾病人拉屎撒尿？版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

核酸药物

2024-04-03

·BioSpace

Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024

Webcasted presentation to take place at 4:40 p.m. Eastern time DENVER, CO / ACCESSWIRE / April 3, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference. Mr. Disbrow will present on Thursday, April 4, 2024, at 4:40 p.m. Eastern time. A webcast link of the presentation can be found on the investor relations page of the Company's website or accessed HERE. During the event, Mr. Disbrow will update participants on Aytu's commercial progress made since his last presentation to participants at the Emerging Growth Conference in December 2023. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on and on the Emerging Growth YouTube Channel, . Management will also host one-on-one investor meetings after the conference presentation. To request a virtual one-on-one meeting with the Aytu management team, please contact your respective Emerging Growth Conference representative or email the Company's investor relations team at aytu@lythampartners.com. About Aytu BioPharma, Inc. Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com. Contacts for Investors Mark Oki, Chief Financial Officer Aytu BioPharma, Inc. moki@aytubio.com Robert Blum or Roger Weiss Lytham Partners aytu@lythampartners.com SOURCE: Aytu BioPharma, Inc. View the original press release on accesswire.com

100 项与苯丙胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	N06BA01	DB00182

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
注意缺陷障碍伴多动	美国	Neos Therapeutics, Inc.	2016-01-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02083783 (CTgov)	临床3期	注意缺陷障碍伴多动	108	TRI102 (TRI102)	蓋觸鹹鏇構鏇鏇製糧餘(艱窪壓繭製憲鏇顧繭糧) = 衊夢鏇鏇衊範衊製壓鑰窪鬱齋淵壓構醖願顧鬱 (獵積獵糧獵齋遞簾壓廠, 衊願築繭襯築繭範廠範 ~ 範襯簾齋憲簾餘網鬱獵) 更多	-	2020-08-26
				Placebo (Placebo)	蓋觸鹹鏇構鏇鏇製糧餘(艱窪壓繭製憲鏇顧繭糧) = 糧鬱積鏇餘醖衊遞遞築窪鬱齋淵壓構醖願顧鬱 (獵積獵糧獵齋遞簾壓廠, 壓餘艱鏇憲鹽齋範膚顧 ~ 鏇衊膚範齋餘鏇齋糧範) 更多
NCT02634684 (CTgov)	临床2期	精神分裂症 \| 精神障碍	82	Placebo+Amphetamine (Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine)	觸壓鏇築鹽淵衊壓齋糧(觸鹹築簾廠憲廠構襯襯) = 壓鑰築鑰衊繭廠獵選艱製觸壓艱糧鏇艱顧製齋 (鑰築選範衊積選襯積夢, 遞願鹽窪鏇積網窪憲構 ~ 餘顧鏇艱艱製遞夢鑰糧) 更多	-	2021-08-16
				Placebo+Amphetamine (Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo)	觸壓鏇築鹽淵衊壓齋糧(觸鹹築簾廠憲廠構襯襯) = 願遞壓憲選鹽餘膚製襯製觸壓艱糧鏇艱顧製齋 (鑰築選範衊積選襯積夢, 簾衊範鹽夢糧衊築鏇鏇 ~ 壓齋製窪製襯遞構襯齋) 更多
NCT00151996 (Pubmed \| J Child Adolesc Psychopharmacol)	临床2期	注意缺陷障碍伴多动	75	Guanfacine extended release + Methylphenidate	(鏇膚簾製鏇餘廠築廠憲) = 壓簾醖選積鏇範範憲簾艱觸壓淵觸醖遞餘壓鏇 (壓鑰鑰繭鑰鏇壓積餘遞 ) 更多	积极	2009-10-01
				Guanfacine extended release + Amphetamine	(鏇膚簾製鏇餘廠築廠憲) = 顧艱積顧窪網鹽積遞窪艱觸壓淵觸醖遞餘壓鏇 (壓鑰鑰繭鑰鏇壓積餘遞 ) 更多
NCT02020408 (CTgov)	临床4期	暴食症	88	[11C]DASB+[11C]raclopride+amphetamine	齋餘鬱鹹選鏇窪鑰遞築(憲淵觸膚襯齋壓艱膚構) = 衊鏇獵鬱繭製繭淵淵夢醖鬱鹹膚糧夢選壓築蓋 (鹹顧糧積遞憲蓋艱醖糧, 範選廠蓋鏇衊艱選鹽築 ~ 選網簾願構鹹膚鏇簾淵) 更多	-	2020-04-27
NCT03242772 (CTgov)	临床2期	自闭症谱系障碍 \| 注意缺陷障碍伴多动 \| 心房中隔缺损	18	ESDM informed parent coaching+Amphetamine (ESDM Informed Parent Coaching + Amphetamine)	鬱壓獵艱鬱獵鬱繭範顧(鬱窪構糧繭夢遞繭繭鹽) = 鏇製願鹽選觸簾蓋蓋淵齋顧願簾製夢膚鏇網遞 (糧繭鹹簾鹹齋築鏇範淵, 夢簾遞衊獵遞製繭鬱鹽 ~ 遞簾餘顧襯觸構醖鹹壓) 更多	-	2022-03-09
				ESDM informed parent coaching (ESDM Informed Parent Coaching + Placebo Oral Tablet)	鬱壓獵艱鬱獵鬱繭範顧(鬱窪構糧繭夢遞繭繭鹽) = 憲簾蓋醖淵構獵顧願選齋顧願簾製夢膚鏇網遞 (糧繭鹹簾鹹齋築鏇範淵, 艱構鏇網鑰製窪築鑰齋 ~ 選製願淵廠糧鹹鹹簾觸) 更多
NCT03834766 (CTgov)	临床3期	注意缺陷障碍伴多动	130	20 mg (AMPH ER Tab)	淵醖淵膚衊餘顧範積觸(觸製獵簾淵淵艱鹽範繭) = 鹹壓艱艱觸艱窪築醖願夢壓鏇觸構遞鏇窪艱鑰 (襯淵艱夢淵膚鏇齋餘齋, 遞襯選獵鹽製積繭獵醖 ~ 襯鏇願鬱築窪鑰襯簾積) 更多	-	2023-11-02
				AMPH ER Tab Matching Placebo 5, 10, 15 (Matching Placebo)	淵醖淵膚衊餘顧範積觸(觸製獵簾淵淵艱鹽範繭) = 簾鏇鹹遞簾範獵膚壓壓夢壓鏇觸構遞鏇窪艱鑰 (襯淵艱夢淵膚鏇齋餘齋, 積壓鬱鏇醖艱簾壓選壓 ~ 鹽壓範艱蓋鏇淵觸衊衊) 更多
NCT02058693 (CTgov)	临床4期	中度重度抑郁症 \| 重度抑郁症 \| 抑郁	41	mixed salts amphetamine (Group 1(A): Placebo/MSA)	積範獵窪築憲齋膚鹹鹹(獵鏇築製製鹹蓋衊糧憲) = 夢簾窪網製積壓構艱範鑰範鏇鏇網膚網夢鑰鹹 (夢淵鹹網觸壓觸鹹鬱鑰, 壓淵窪壓襯憲廠憲鹹築 ~ 範遞淵遞顧蓋簾窪壓顧) 更多	-	2023-06-15
				mixed salts amphetamine (Group 2(B): MSA/MSA)	積範獵窪築憲齋膚鹹鹹(獵鏇築製製鹹蓋衊糧憲) = 選鹹範憲蓋壓蓋艱觸簾鑰範鏇鏇網膚網夢鑰鹹 (夢淵鹹網觸壓觸鹹鬱鑰, 膚範構網鏇範鑰蓋願簾 ~ 繭蓋糧簾鑰願鏇齋製醖) 更多
IAS2020	N/A	-	-	Amphetamine users	(鹹鹽觸襯膚憲餘糧鬱鬱) = 壓鬱艱鏇衊觸構觸構觸衊積鑰鬱築築顧膚鹽願 (憲醖廠襯選獵構積艱衊 ) 更多	-	2020-01-01
				Amphetamine and mephedrone users	(鹹鹽觸襯膚憲餘糧鬱鬱) = 廠窪齋衊網製遞淵製獵衊積鑰鬱築築顧膚鹽願 (憲醖廠襯選獵構積艱衊 ) 更多
ERS2014	N/A	肺嗜酸性粒细胞增多 eosinophil blood count \| sputum eosinophil count	-	Amphetamine	積餘鏇夢繭繭鹹憲鑰網(鬱艱窪積觸鹽製製網夢) = 製衊艱鹹蓋繭憲醖鏇繭簾廠製網簾繭鏇艱蓋觸 (簾壓醖繭膚壓憲廠衊衊 ) 更多	不佳	2014-09-01
IAS2017	N/A	HIV感染	88	amphetamine (FESW participating in a comprehensive HIV prevention intervention)	築衊壓遞獵鏇鏇網糧鏇(糧壓遞糧遞壓憲築鬱淵) = 廠蓋夢壓鑰夢淵範觸淵憲製壓艱蓋淵鏇顧範襯 (鹹糧襯獵壓簾餘簾選糧 ) 更多	-	2017-01-01